| |
|
A new genetic engineering approach to generate human antibodies
using transgenic rats.
OMT's antibody platform presents an exclusive opportunity for pharmaceutical companies to investigate all non-proprietary targets — even those previously restricted - using a new, powerful human antibody platform.
The key features of OMT's new platform are:
-
Fully Human Monoclonal Antibodies
- Based on Transgenic Rats
- Freedom-To-Operate
- Novel Patented Technology
- Rapid Development and Commercialization
In 2011, OMT will begin partnering with a limited number of companies interested in evaluating its human antibody platform.
|
|
|
|
